ArticleAnnals of surgical oncology2026
Chest Wall Perforator Flaps in Oncoplastic Breast Surgery: A Series of 157 Consecutive Cases at the Paris Breast Center.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Expanding the Boundaries of Breast Conservation with Chest Wall Perforator Flaps.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChest wall perforator flaps (CWPF) are emerging as a versatile and safe oncoplastic technique for breast-conserving surgery, particularly in small to medium breasts and challenging tumor locations. Despite proven benefits, their adoption remains limited by the lack of long-term real-world data.
methodsA single-institution retrospective analysis was conducted to assess CWPF outcomes in 157 patients with early-stage breast cancer treated at the Paris Breast Center between 2005 and 2024. Primary outcomes were complication rates, re-excision, and conversion to mastectomy rates. Secondary outcomes included local and distant recurrence, and overall survival with median follow-up exceeding 4 years.
resultsThe median age was 60 years; most tumors were cT1-T2 with median size 14.4 mm. CWPF types were anterior intercostal artery perforator (AICAP; 70.7%), lateral intercostal artery perforator (LICAP; 18.5%), LICAP + lateral thoracic artery perforator (LTAP; 6.4%), and LTAP (4.5%). Early complications (grade ≥II) occurred in 5.1% with no partial or total flap loss. The rate of re-excision was 5.7% and of completion mastectomy was 0.6%. The median follow-up was 48 months; local recurrence occurred in 2.5% and distant recurrence in 6.4%, with no deaths.
conclusionsCWPF reinforces the evolving role of oncoplastic surgery in safely extending breast-conserving opportunities, including neoadjuvant systemic therapy and re-operative settings. Prospective, multicentric studies including patient-reported outcomes are warranted to further validate these findings.
Indexed as
Identifiers
42323460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.